147 related articles for article (PubMed ID: 25388286)
21. Getting Syk: spleen tyrosine kinase as a therapeutic target.
Geahlen RL
Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness.
Matsubara S; Li G; Takeda K; Loader JE; Pine P; Masuda ES; Miyahara N; Miyahara S; Lucas JJ; Dakhama A; Gelfand EW
Am J Respir Crit Care Med; 2006 Jan; 173(1):56-63. PubMed ID: 16192454
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors.
Norman P
Expert Opin Ther Pat; 2012 Mar; 22(3):335-9. PubMed ID: 22356552
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
[TBL] [Abstract][Full Text] [Related]
27. The ability of an ethanol extract of Cinnamomum cassia to inhibit Src and spleen tyrosine kinase activity contributes to its anti-inflammatory action.
Yu T; Lee S; Yang WS; Jang HJ; Lee YJ; Kim TW; Kim SY; Lee J; Cho JY
J Ethnopharmacol; 2012 Jan; 139(2):566-73. PubMed ID: 22155395
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract][Full Text] [Related]
29. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
30. Distinct role of spleen tyrosine kinase in the early phosphorylation of inhibitor of kappaB alpha via activation of the phosphoinositide-3-kinase and Akt pathways.
Lee YG; Chain BM; Cho JY
Int J Biochem Cell Biol; 2009 Apr; 41(4):811-21. PubMed ID: 18775507
[TBL] [Abstract][Full Text] [Related]
31. [Functions of spleen tyrosine kinase (Syk) gene and its correlation to neoplasms].
Wang HY; Zhang ZX
Ai Zheng; 2007 May; 26(5):555-60. PubMed ID: 17672952
[TBL] [Abstract][Full Text] [Related]
32. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
33. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
34. Proteomic and genetic approaches identify Syk as an AML target.
Hahn CK; Berchuck JE; Ross KN; Kakoza RM; Clauser K; Schinzel AC; Ross L; Galinsky I; Davis TN; Silver SJ; Root DE; Stone RM; DeAngelo DJ; Carroll M; Hahn WC; Carr SA; Golub TR; Kung AL; Stegmaier K
Cancer Cell; 2009 Oct; 16(4):281-94. PubMed ID: 19800574
[TBL] [Abstract][Full Text] [Related]
35. Syk protein tyrosine kinase involves PECAM-1 signaling through tandem immunotyrosine inhibitory motifs in human THP-1 macrophages.
Wang J; Wu Y; Hu H; Wang W; Lu Y; Mao H; Liu X; Liu Z; Chen BG
Cell Immunol; 2011; 272(1):39-44. PubMed ID: 22000807
[TBL] [Abstract][Full Text] [Related]
36. Identification of BCAR-1 as a new substrate of Syk tyrosine kinase through a determination of amino acid sequence preferences surrounding the substrate tyrosine residue.
Kim JY; Huh K; Jung R; Kim TJ
Immunol Lett; 2011 Mar; 135(1-2):151-7. PubMed ID: 21047529
[TBL] [Abstract][Full Text] [Related]
37. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Zhao H; Caflisch A
Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110
[TBL] [Abstract][Full Text] [Related]
38. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas.
Rinaldi A; Ponzoni M; Uccella S; Rossi D; Gaidano G; Facchetti F; Pruneri G; Tibiletti MG; Capella C; Zucca E; Doglioni C; Catapano C; Bertoni F
Hematol Oncol; 2011 Sep; 29(3):164-6. PubMed ID: 21416481
[No Abstract] [Full Text] [Related]
39. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.
Young RM; Hardy IR; Clarke RL; Lundy N; Pine P; Turner BC; Potter TA; Refaeli Y
Blood; 2009 Mar; 113(11):2508-16. PubMed ID: 18981293
[TBL] [Abstract][Full Text] [Related]
40. 4-Chlorotetrazolo[1,5-a]quinoxaline inhibits activation of Syk kinase to suppress mast cells in vitro and mast cell-mediated passive cutaneous anaphylaxis in mice.
Park KL; Ko NY; Lee JH; Kim DK; Kim HS; Kim AR; Her E; Kim B; Kim HS; Moon EY; Kim YM; Kim HR; Choi WS
Toxicol Appl Pharmacol; 2011 Dec; 257(2):235-41. PubMed ID: 21958720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
